Noom Review

What They Offer

Noom Med combines the company's decade-plus behavioral-change expertise with clinical GLP-1 prescribing. As of this review, Noom runs six distinct named programs rather than a single plan: Microdose GLP-1Rx, GLP-1Rx (semaglutide-class), GLP-1Rx Plus (tirzepatide-class), Proactive Health GLP-1Rx (microdosing plus at-home biomarker testing), a non-GLP-1 Metformin weight-loss pill, and a Telehealth for Branded Meds track for patients who want an FDA-approved medication such as Ozempic, Wegovy, Zepbound or Mounjaro billed through insurance. The GLP-1 tiers use what Noom calls its SmartDose protocol — a gradual, personalized titration schedule adjusted roughly every two weeks based on weight-loss speed and side effects. Every clinical plan includes Noom's psychology-based curriculum, in-app tracking, and clinical care team access.

Pricing Table

The number on Noom's pricing page is a monthly figure, but most of these programs bill quarterly. Read the "Billed" column, not just the "Ongoing" column, before you sign up. Figures below are from noom.com/med/pricing/, verified 2026-08-12.

All programs above are FSA/HSA-eligible except the Telehealth for Branded Meds track. Noom does not publish a state-by-state availability list; check eligibility during signup for your state.

What's Included

• Psychology-based behavioral change curriculum
• SmartDose adaptive medication titration
• Clinical care team (ongoing monitoring and adjustments)
• In-app food logging and progress tracking
• Medication management and prescription renewals
• Side effect management support
• Access to Noom's weight management app

Eligibility

Clinical Results & Effectiveness

What Noom's own peer-reviewed research shows — about the behavioral app, not the GLP-1 program: a retrospective analysis of more than 11,000 Noom users, published in JMIR mHealth and uHealth, found that greater engagement with the digital program was associated with clinically meaningful weight loss (Carey A, et al., 2021; doi:10.2196/30622). More recently, a 427-person randomized controlled trial published in Obesity Science & Practice found that Noom Weight members lost an average of 4.05% of body weight at 68 weeks, versus a 1.46% gain in a control group that received standard dietary-guideline education (McCallum et al., 2026; doi:10.1002/osp4.70122). Both studies describe Noom's behavior-change program — neither is about the GLP-1 medication itself.

What Noom reports about its GLP-1 program specifically — self-reported company data, not an independent trial: Noom's own pricing pages cite the top 25th percentile of self-reported data from 1,185 Microdose GLP-1Rx users to support a "lose up to 17 pounds in 60 days" claim; the average across that full sample was lower, at 13 pounds. A separate Noom press release describes a subgroup of 141 GLP-1Rx Program members who had already reached at least 5% body-weight loss, reporting they averaged 14.3% loss "by the time they stopped medication" — a figure drawn from people pre-selected for early success, not a starting expectation, and Noom's own release explicitly labels its engagement findings as observational associations, "not proof that engagement causes improved outcomes." None of these figures isolate the medication from the behavioral coaching that comes bundled with it.

What we removed: an earlier version of this page stated Noom's clinical program achieves "approximately 15% body weight reduction, consistent with published GLP-1 trial data" — implying the STEP/SURMOUNT trials of FDA-approved semaglutide and tirzepatide validate Noom's own program. Those trials tested the drugs themselves, not Noom's compounded formulations or its behavioral bundle, so that inference does not hold; it is the same substitution the National Advertising Division ruled against in a different provider's advertising in December 2025. For patients on Noom's Telehealth for Branded Meds track who are prescribed the actual FDA-approved drug, published trial data on that specific medication is relevant to what you can expect from the medication itself — see our explainer on how GLP-1 medications work.

Noom's SmartDose titration protocol — adjusting dose roughly every two weeks based on weight-loss speed and side effects — is a described mechanism, not itself a clinical-outcomes claim; we found no independent published data isolating SmartDose's effect on outcomes versus standard titration.

Refund Policy and Cancellation: Read This Before You Sign Up

There is no weight-loss guarantee on Noom Med. Per Noom's own published refund policy, a Noom Med charge is refundable only if you request it before a prescription has been written; once a prescription is issued, the charge is final regardless of outcome. The separate Telehealth for Branded Meds track allows a refund within 7 days of your first charge, but only if no clinical visit has taken place yet. Noom Weight (the non-medical app) has a different, unrelated 14-day refund window that does not apply to Noom Med.

Cancellation: you can cancel anytime through the in-app Subscription Portal, but per Noom's support documentation your subscription "stays active until the end of the current billing cycle, even if you cancel mid-cycle" — and uninstalling the app does not cancel it. Combined with the quarterly billing on most GLP-1 tiers, missing the cancellation window before a renewal means being charged for another full ~12-week cycle with no refund available.

Sources: Noom Refund Policy and How to Cancel Your Noom Subscription, both read at source.

Is Noom Legitimate? Regulatory and Legal History

Noom is a real, long-operating company, not a scam. It does have regulatory and legal history worth knowing before you sign up — both items concern advertising and billing practices, not drug safety or patient harm.

NAD advertising decision, May 26, 2026 (BBB National Programs, Case #7539). Competitor Eli Lilly challenged Noom's Microdose GLP-1Rx marketing message "A Smaller Dose. A Smarter Start." The National Advertising Division found Noom had not substantiated the implication that the lower dosage itself delivers a measurable health benefit, and recommended Noom modify or discontinue the claim. Noom said it disagreed with the conclusion but voluntarily agreed to comply, and separately discontinued other challenged dosing and efficacy claims. This is an industry self-regulatory advertising decision, not a government enforcement action, and Noom complied rather than refusing. Read the decision at bbbprograms.org.

Class-action settlement, resolved February 2022 (not an FTC action). Geraldine Mahood v. Noom, Inc. (S.D.N.Y., Case No. 1:20-cv-03677) was a private class-action lawsuit, not an FTC enforcement action, alleging Noom's free-trial signup made cancellation difficult enough that users were charged for unwanted auto-renewals. Noom settled for $62 million ($56 million cash plus $6 million in subscription credits) without admitting wrongdoing; the settlement required clearer auto-renewal disclosures and an easier cancellation process. This matter is fully resolved, not pending. We searched FTC.gov and found no FTC enforcement action against Noom specifically — the widely cited "$56 million Noom settlement" is this private lawsuit, and characterizing it as an FTC action would be inaccurate.

FDA: we searched FDA's warning-letter database directly and found no warning letter addressed to Noom as of this review (2026-08-12). Compounded-GLP-1 telehealth is an active enforcement area with new letters issued in batches through 2025 and 2026, so this could change; we will update this page if that happens.

Customer Experience

Noom benefits from brand recognition built over years as a leading weight-management app, and the clinical GLP-1 program inherits that infrastructure. Users commonly describe the behavioral coaching component positively but note the app can feel notification-heavy. We could not verify any third-party rating figures (BBB grade, Trustpilot score, app-store rating) specifically for Noom Med at their own source as of this review, so none are published on this page — check current ratings directly on Trustpilot, the App Store, or Google Play before relying on a number.

Our Verdict

Disclosures

Frequently Asked Questions